Breaking News
December 10, 2018 - Scientists find answers to how cancer spreads
December 10, 2018 - Study explores why older people read more slowly
December 10, 2018 - Asbestos found in most NHS hospitals finds BBC inquiry
December 10, 2018 - Researchers use new technique to probe hydrogen bonds
December 10, 2018 - Music improves social communication in autistic children
December 10, 2018 - Some Brain Tumors May Respond to Immunotherapy, New Study Suggests
December 10, 2018 - Banning junk food ads to combat childhood obesity
December 10, 2018 - Skin Autofluorescence Predicts T2DM, Heart Disease, Mortality
December 10, 2018 - Largest autism sequencing study to date yields 102 genes associated with ASD
December 10, 2018 - Statins associated with low risk of side effects
December 10, 2018 - Study explores how schools address adolescent self-harming practices
December 10, 2018 - Pregnancy in adolescence linked to increased risks of complications in young mothers
December 10, 2018 - Risk Analysis publishes special issue on communicating about Zika virus
December 10, 2018 - Botox May Help Prevent Post-Op A-Fib
December 10, 2018 - African-American mothers rate boys higher for ADHD
December 10, 2018 - Graphic warning labels cancel out cigarettes’ appeal to young people
December 10, 2018 - Australian researchers to study gas inhalational anaesthetic and likelihood of cancer return
December 10, 2018 - Individual neurons located within the brain have implications for psychiatric diseases
December 10, 2018 - Researchers improve bariatric surgery scoring system to extend prediction time for diabetic remission
December 10, 2018 - HPV type 16 or 18 associated with cervical cancer risk in young women
December 10, 2018 - Cervical cancer risk is higher in women with positive HPV, but no cellular abnormalities
December 10, 2018 - Combo therapy not needed if low RA disease activity achieved
December 10, 2018 - Novel therapeutic targets based on biology of aging show promise for Alzheimer’s disease
December 10, 2018 - UC San Diego professor receives NCI Outstanding Investigator Award for cancer research
December 10, 2018 - Study evaluates placental mesenchymal stem cell sheets for myocardial repair and regeneration
December 10, 2018 - Blueprint Medicines Announces Updated Results from Ongoing EXPLORER Clinical Trial of Avapritinib Demonstrating Broad Clinical Activity and Significant Symptom Reductions in Patients with Systemic Mastocytosis
December 10, 2018 - Study clarifies ApoE4’s role in dementia
December 10, 2018 - Eating disorders now a top priority with Australian Government
December 10, 2018 - Neuronal activity in the brain allows prediction of risky or safe decisions
December 10, 2018 - FDA Alerts Health Care Professionals and Patients Not to Use Drug Products Intended to be Sterile from Promise Pharmacy
December 10, 2018 - Improving dementia care and treatment saves thousands of pounds in care homes
December 10, 2018 - Heroin-assisted treatment can offer benefits, reduce harms
December 10, 2018 - People covered by Michigan’s expanded Medicaid program report improvements in health, finds study
December 10, 2018 - Hazelnuts improve micronutrient levels in older adults
December 9, 2018 - History of Partner Violence Tied to Menopause Symptoms
December 9, 2018 - Clean Up Safely After a Disaster|Natural Disasters and Severe Weather
December 9, 2018 - Drug wholesalers drove fentanyl’s deadly rise, report concludes
December 9, 2018 - Deprescribing could help manage polypharmacy in older adults
December 9, 2018 - Retraction of article “Joy of cooking too much” from journal
December 9, 2018 - FDA Warns of Rare Stroke Risk With MS Drug Lemtrada (Alemtuzumab)
December 9, 2018 - Feds say heroin, fentanyl remain biggest drug threat to US
December 9, 2018 - Eliminating microglia can reverse some aspects of stress sensitization, study shows
December 9, 2018 - New genetic insight could help treat rare debilitating heart and lung condition
December 9, 2018 - MiRagen Therapeutics Announces Final Safety, Biodistribution and Clinical Efficacy Data From Phase 1 Cobomarsen Clinical Trial in Patients With Mycosis Fungoides
December 9, 2018 - Work with your doctor to weigh pros, cons of treatment options for hyperthyroidism
December 9, 2018 - CWRU researcher secures $14.6 million funding for genetic study into Alzheimer’s disease
December 9, 2018 - High intensity statin treatment and adherence could save more lives
December 9, 2018 - Surgery patients use only 1/4 of prescribed opioids, and prescription size matters
December 9, 2018 - AXT offers Phi Optics upgrade to QPI systems for inverted light microscopes
December 9, 2018 - New booklet could help improve conditions of young pupils with albinism
December 9, 2018 - Few Physicians Work in Practices That Use Telemedicine
December 9, 2018 - Older Adults and Oral Health
December 9, 2018 - Health utility values improve after septorhinoplasty
December 9, 2018 - New EU-funded project provides insight into how the brain develops
December 9, 2018 - Expanded use of tele-emergency services can help strengthen rural hospitals
December 9, 2018 - Infections in the Young May Be Tied to Risk for Mental Illness: Study
December 9, 2018 - Profile: Native Hawaiians and Pacific Islanders
December 9, 2018 - Snoring poses greater cardiac risk to women
December 9, 2018 - Researcher takes further steps in understanding how and why cute aggression occurs
December 9, 2018 - Researchers create new light-activated tools for controlling neurons
December 9, 2018 - Spinal cord injury disrupts the body’s internal clock, study shows
December 9, 2018 - Babies recognize nested structures similar to our grammar
December 9, 2018 - UT Austin researcher receives $2.5 million CZI grant for neurodegenerative disease research
December 9, 2018 - Sleep problems found to be prevalent and increasing among college students
December 9, 2018 - Study reveals why some children are susceptible to the effects of maltreatment
December 9, 2018 - Study investigates influence of different opioids on driving performance
December 9, 2018 - Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia
December 9, 2018 - Eliminating microglia prevents heightened immune sensitivity after stress
December 9, 2018 - Boys with social difficulties are at greatest risk of early substance use
December 9, 2018 - ‘Wrong’ connective tissue cells linked to worse prognosis in breast cancer patients
December 8, 2018 - Chronic, refractory schizophrenia patients benefit from targeted cognitive training
December 8, 2018 - Advertising in kids’ apps more prevalent than parents may realize
December 8, 2018 - New way to trace the transmission histories of rare genetic diseases
December 8, 2018 - ASH: A+CHP Bests CHOP for Peripheral T-Cell Lymphoma
December 8, 2018 - Results of pediatric genomic epilepsy tests often reclassified
December 8, 2018 - New way of controlling HIV latency to completely eradicate the virus
December 8, 2018 - Phasefocus to showcase the Livecyte 2 at ASCB
December 8, 2018 - KHN’s ‘What the Health?’ Is health spending the next big political issue?
December 8, 2018 - Mussels take in microplastic pollution fibers and flush most of them out again
December 8, 2018 - AHA: How to Stop Smoking … for Good
Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

image_pdfDownload PDFimage_print

What is a beta-2 microglobulin tumor marker test?

This test measures the amount of a protein called beta-2 microglobulin (B2M) in the blood, urine, or cerebrospinal fluid (CSF). B2M is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body.

B2M is found on the surface of many cells and is released into the body. Healthy people have small amounts of B2M in their blood and urine.

  • People with cancers of the bone marrow and blood often have high levels of B2M in their blood or urine. These cancers include multiple myeloma, lymphoma, and leukemia.
  • High levels of B2M in cerebrospinal fluid can mean that cancer has spread to the brain and/or spinal cord.

A B2M tumor marker test is not used to diagnose cancer. But it can provide important information about your cancer, including how serious it is and how it may develop in the future.

Other names: total beta-2 microglobulin, β2-microglobulin, B2M

What is it used for?

A beta-2 microglobulin tumor marker test is most often given to people who have been diagnosed with certain cancers of the bone marrow or blood. The test may be used to:

  • Figure out the severity of cancer and whether it has spread. This process is known as cancer staging. The higher the stage, the more advanced the cancer is.
  • Predict disease development and guide treatment.
  • See if cancer treatment is effective.
  • See if cancer has spread to the brain and spinal cord.

Why do I need a beta-2 microglobulin tumor marker test?

You may need this test if you have been diagnosed with multiple myeloma, lymphoma, or leukemia. The test can show the stage of your cancer and whether your cancer treatment is working.

What happens during a beta-2 microglobulin tumor marker test?

A beta-2 microglobulin test is usually a blood test, but may also be given as a 24-hour urine test, or as a cerebrospinal fluid (CSF) analysis.

For a blood test, a health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.

For a 24-hour urine sample, your health care provider or a laboratory professional will give you a container to collect your urine and instructions on how to collect and store your samples. A 24-hour urine sample test usually includes the following steps:

  • Empty your bladder in the morning and flush that urine away. Record the time.
  • For the next 24 hours, save all your urine in the container provided.
  • Store your urine container in the refrigerator or a cooler with ice.
  • Return the sample container to your health provider’s office or the laboratory as instructed.

For a cerebrospinal fluid (CSF) analysis, a sample of spinal fluid will be collected in a procedure called a spinal tap (also known as a lumbar puncture). A spinal tap is usually done in a hospital. During the procedure:

  • You will lie on your side or sit on an exam table.
  • A health care provider will clean your back and inject an anesthetic into your skin, so you won’t feel pain during the procedure. Your provider may put a numbing cream on your back before this injection.
  • Once the area on your back is completely numb, your provider will insert a thin, hollow needle between two vertebrae in your lower spine. Vertebrae are the small backbones that make up your spine.
  • Your provider will withdraw a small amount of cerebrospinal fluid for testing. This will take about five minutes.
  • You’ll need to stay very still while the fluid is being withdrawn.
  • Your provider may ask you to lie on your back for an hour or two after the procedure. This may prevent you from getting a headache afterward.

Will I need to do anything to prepare for the test?

You don’t need any special preparations for a blood or urine test.

You don’t need any special preparations for a CSF analysis, but you may be asked to empty your bladder and bowels before the test.

Are there any risks to the test?

There is very little risk to having a blood or urine test. After a blood test, you may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.

There is very little risk to having a spinal tap. You may feel a little pinch or pressure when the needle is inserted. After the test, you may get a headache, called a post-lumbar headache. About one in ten people will get a post-lumbar headache. This can last for several hours or up to a week or more. If you have a headache that lasts longer than several hours, talk to your health care provider. He or she may be able to provide treatment to relieve the pain. You may feel some pain or tenderness in your back at the site where the needle was inserted. You may also have some bleeding at the site.

What do the results mean?

If the test was used to find out how advanced your cancer is (cancer stage), the results may show how much cancer is in your body and whether it is likely to spread.

If the B2M test was used to check how well your treatment is working, your results may show:

  • Your B2M levels are increasing. This may mean your cancer is spreading, and/or your treatment is not working.
  • Your B2M levels are decreasing. This may mean your treatment is working.
  • Your B2M levels have not increased or decreased. This may mean your disease is stable.
  • Your B2M levels decreased, but then later increased. This may mean your cancer has come back after you’ve been treated.

If you have questions about your results, talk to your health care provider.

Is there anything else I need to know about a beta-2 microglobulin tumor marker test?

Beta-2 microglobulin tests are not always used as tumor marker tests for cancer patients. B2M levels are sometimes measured to:

  • Check for kidney damage in people with kidney disease.
  • Find out if a viral infection, such as HIV/AIDS, has affected the brain and/or spinal cord.
  • Check to see if disease has advanced in people with multiple sclerosis, a chronic disease affecting the brain and spinal cord.
Tagged with:

About author

Related Articles